CareDx Shares Rise 10% After AlloSure Lung Testing Service Receives Medicare Coverage

By Chris Wack

CareDx shares were up 10% at $10.69 after the company said its AlloSure Lung donor-derived cell-free DNA molecular testing service has received Medicare coverage.

The company said the MolDX technology assessment program has determined that AlloSure Lung will be covered under the existing Medicare Local Coverage Determination for Molecular Testing for Solid Organ Allograft Rejection for use in the surveillance setting in lung transplant patients, effective May 9.

CareDx said AlloSure Lung has been validated to effectively identify a composite endpoint of acute cellular rejection, antibody-mediated rejection, and infection in asymptomatic lung transplant patients during routine surveillance screening. Company studies showed that when using an AlloSure Lung surveillance strategy, it was estimated that there were 83% fewer invasive biopsies than would have been performed under a surveillance biopsy protocol.

AlloSure Lung has already been adopted in more than 60% of lung transplant centers, the CareDx said.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

July 11, 2023 10:36 ET (14:36 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.